Fran­chise killer: Are Re­gen­eron and Sanofi about to get hand­ed their walk­ing pa­pers on PC­SK9?

One top an­a­lyst be­lieves that the Med­i­cines Com­pa­ny may soon be in a po­si­tion to do what years of pay­er re­sis­tance to Re­gen­eron and Sanofi’s would-be PC­SK9 block­buster Pralu­ent has so far failed to do: 

Kill it.

So here’s the rea­son­ing, and it’s com­pelling.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.